Prognostic role of inflammatory biomarkers in HIV-infected patients with a first diagnosis of hepatocellular carcinoma: A single-center study.


Journal

Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876

Informations de publication

Date de publication:
02 2019
Historique:
received: 17 06 2018
accepted: 01 09 2018
pubmed: 15 9 2018
medline: 17 1 2020
entrez: 15 9 2018
Statut: ppublish

Résumé

To assess hepatocellular carcinoma (HCC) survival and to investigate the prognostic role of immunonutritional biomarkers, as neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR) and prognostic nutritional index (PNI), in a cohort of human immunodeficiency virus (HIV)-infected patients. All HIV-positive patients diagnosed with HCC at our Department from January 2000 to December 2013 were included. The outcomes were overall survival (OS), recurrence-free survival (RFS), and liver-related death (LRD). To examine the role of inflammatory biomarkers on the outcomes, univariate and multivariable Cox regression models were used. Receiver operating characteristic (ROC) curves were implemented to evaluate the prediction role of NLR, PLR, and PNI. A total of 40 patients (90% males) with a mean age of 48.3 years (SD = 5.6) were recruited. NLR ≥ 2.9 was associated with all causes mortality, as well as, PLR ≥ 126. NLR and PLR were predictors of OS, RFS, and LRD, while PNI did not emerge as a prognostic marker. According to the multivariate analysis, no HCC treatment was the only risk factor associated with risk of death. The areas under the ROC curves were 68.3 (95% confidence interval [CI], 54.5-82.1) for PLR and 66.3 (95% CI, 54.3-78.2) for NLR at 3 years; similar results were found at 5 years of follow-up. Although, if examined singularly, NLR and PLR are prognostic factors for HCC recurrence and survival in HIV-infected patients, at the multivariate analysis, "no HCC treatment" remains the only independent risk factor associated with fatal outcome.

Identifiants

pubmed: 30216474
doi: 10.1002/jmv.25317
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

241-248

Informations de copyright

© 2018 Wiley Periodicals, Inc.

Auteurs

Eugenia Quiros-Roldan (E)

Department of Infectious and Tropical Diseases, ASST Spedali Civili General Hospital, University of Brescia, Brescia, Italy.

Martina Properzi (M)

Department of Infectious and Tropical Diseases, ASST Spedali Civili General Hospital, University of Brescia, Brescia, Italy.

Silvia Amadasi (S)

Division of General Medicine, ASST Garda, Manerbio, Italy.

Elena Raffetti (E)

Department of Public Health Sciences, Karolinska Institutet, Stockholm, Sweden.

Alice Ferraresi (A)

Department of Infectious and Tropical Diseases, ASST Spedali Civili General Hospital, University of Brescia, Brescia, Italy.

Luciano Biasi (L)

Department of Infectious and Tropical Diseases, ASST Spedali Civili General Hospital, University of Brescia, Brescia, Italy.

Emanuele Focà (E)

Department of Infectious and Tropical Diseases, ASST Spedali Civili General Hospital, University of Brescia, Brescia, Italy.

Francesco Castelli (F)

Department of Infectious and Tropical Diseases, ASST Spedali Civili General Hospital, University of Brescia, Brescia, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH